Update
$FibroGen(FGEN.US$ FibroGen Announces Presentation of Positive Interim Data From the Phase 1B Study of FG-3246 (for46) in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc) at the 2024 American Society of Clinical Oncology Annual Meeting
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
